SIGA Technologies (SIGA) Intrinsic Value Calculator

Updated: Nov 19, 2026

SIGA Technologies (SIGA) trades at $2.65, below its base-case intrinsic value of $4.61 — an implied 74% margin of safety. The model starts from $1.06 in expected earnings per share, grows it at 25.0% annually (analyst consensus) decaying to a 4% terminal rate by Year 5, applies a 3.6x exit multiple, and discounts the result back at 10% per year. The discount suggests the market expects slower growth or a lower multiple than the base case; use the sliders below to stress-test how much growth deterioration the current price already absorbs.

Undervalued by 74.1%
Current Price
$2.65
Intrinsic Value
$4.61
Implied Upside: +74.1%

Discounted Cash Flow with Growth Decay Model

Customize Your Valuation

Adjust the assumptions below to model different scenarios. The intrinsic value updates in real-time.

Conservative
Base Case
Aggressive
Time Horizon 5 years
3 years 10 years
Initial Growth Rate 25.0%
0% (No Growth) 50% (High Growth)
Terminal Growth Rate 4.0%
0% (Decline) 6% (GDP+)
Discount Rate (Required Return) 10.0%
5% (Low Risk) 15% (High Risk)
Exit PE Multiple 3.6x
8x (Value) 40x (Growth)
Calculated Intrinsic Value
$4.61
--
Tradestie Long-Horizon Cycle Intelligence (2016–2025 • Split-Invariant)

Tradestie Long-Horizon Financial Resilience & Peer Growth Benchmark (10-Year Cycle Analysis)

Outside-View Peer Growth Benchmark Pharmaceutical Preparations • 2498+ US Equities Benchmarked

Across 19 years of multi-cycle financial history in Pharmaceutical Preparations, only 37.0% of peer companies at all-scale revenue scale (2020 historical 5-year windows; industry median CAGR: 7.6%/yr) sustained ≥15%/yr 5-year compound revenue growth (broad all-scale equity base rate: 26.2%).

≥5%/yr (5Y)
56.1%
All all-scale: 57.1%
≥10%/yr (5Y)
44.7%
All all-scale: 37.8%
≥15%/yr (5Y)
37.0%
All all-scale: 26.2%
≥20%/yr (5Y)
30.2%
All all-scale: 19.3%
≥25%/yr (5Y)
25.9%
All all-scale: 14.6%
≥30%/yr (5Y)
23.1%
All all-scale: 11.3%
10-Yr Revenue Scale
$15M → $95M
9Y CAGR: +22.7%/yr • 5Y: -5.4%
2008–2009 Cycle Trough Floor
Post-2009 Series
Tracked from FY2016
2022 Rate-Shock Floor
38.5% Op Margin
FY2022 Rev: $111M (-17.1% YoY)
Latest vs Cycle Median Margin
25.1% vs 50.4% med
Secular Scale-Up (Early Trough -> High-Margin Leader)
Multi-Cycle Revenue & Operating Margin Trajectory (2016–2025) Expansion 2008–09 / 2022 Macro Stress
'16
-154%
'17
74%
'18
-9%
'19
68%
'20
67%
'21
39%
'22
60%
'23
50%
'24
25%
'25
Inspect All 10 Fiscal Years of Annual Revenue & Operating Margin History Toggle Annual Ledger ↓
Fiscal Year Annual Revenue YoY Growth Operating Income Operating Margin Macro Cycle Regime
FY2025 (2025-12) $95M -31.8% $24M 25.1% Standard
FY2024 (2024-12) $139M -0.9% $70M 50.4% Standard
FY2023 (2023-12) $140M +26.3% $84M 59.8% Standard
FY2022 (2022-12) $111M -17.1% $43M 38.5% 2022 Rate Shock
FY2021 (2021-12) $134M +7.0% $89M 66.7% Standard
FY2020 (2020-12) $125M +367.3% $85M 67.6% Standard
FY2019 (2019-12) $27M -94.4% -$2M -8.7% Standard
FY2018 (2018-12) $477M +3788.3% $355M 74.4% Standard
FY2017 (2017-12) $12M -18.1% -$19M -153.6% Standard
FY2016 (2016-12) $15M — N/A — Standard

Year-by-Year Projections

EPS growth decays from initial rate to terminal rate over the projection period.

Year Growth Rate EPS Stock Price Present Value

Price Projection

Sensitivity Analysis

How intrinsic value changes with different growth and discount rate assumptions.

Model Inputs
Base EPS $1.06
Current Price $2.65
Historical PE 3.6x
Analyst Growth Est. 25.0%
How It Works

Growth Decay Model: We project EPS growth that gradually slows from the initial rate to a terminal rate (typically 3-4%, matching long-term GDP growth).

Terminal Value: At the end of the projection period, we apply an exit PE multiple to estimate the future stock price.

Discounting: Future values are discounted back to today using your required rate of return (discount rate).